<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03944031</url>
  </required_header>
  <id_info>
    <org_study_id>17220</org_study_id>
    <secondary_id>I9X-MC-MTAB</secondary_id>
    <nct_id>NCT03944031</nct_id>
  </id_info>
  <brief_title>A Study of the Effects of LY3372689 on the Brain in Healthy Participants</brief_title>
  <official_title>Assessment of Brain O-GlcNAcase (OGA) Enzyme Occupancy After Single Oral Doses of LY3372689 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]LSN3316612 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study
      will be conducted in healthy participants and will last up to approximately 25 days after
      enrollment. Screening must be completed within 28 days prior to enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2019</start_date>
  <completion_date type="Actual">February 19, 2020</completion_date>
  <primary_completion_date type="Actual">February 19, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent O-GlcNAcase (OGA) Enzyme Occupancy (EO)</measure>
    <time_frame>Predose Scan (Days -14 to -1)</time_frame>
    <description>Percent OGA EO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent OGA EO</measure>
    <time_frame>Postdose Scan 1 (Days 1 - 4)</time_frame>
    <description>Percent OGA EO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent OGA EO</measure>
    <time_frame>Postdose Scan 2 (Days 2 - 4)</time_frame>
    <description>Percent OGA EO</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3372689 + [18F]LSN3316612</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3372689 administered orally followed by [18F]LSN3316612 PET tracer administered intravenously (IV) approximately 2 - 72 hours later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3372689</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3372689 + [18F]LSN3316612</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>[18F]LSN3316612</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>LY3372689 + [18F]LSN3316612</arm_group_label>
    <other_name>[18F]MNI-1068</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males or females who cannot get pregnant

          -  Have a body mass index (BMI) of at least 18.5 kilogram per square meter (kg/mÂ²),
             inclusive, at screening

          -  Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood
             and urine laboratory test results that are acceptable for the study

          -  Have veins and arteries suitable for protocol required blood sampling

        Exclusion Criteria:

          -  Have a history of head injury or contraindications to undergoing magnetic resonance
             imaging (MRI) examination

          -  Are currently participating in or completed a clinical trial within the last 30 days
             or any other type of medical research judged to be incompatible with this study

          -  Have previously participated or withdrawn from this study

          -  Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop
             smoking for study procedure

          -  Have or used to have health problems or laboratory test results or ECG readings that,
             in the opinion of the doctor, could make it unsafe to participate or could interfere
             with understanding the results of the study

          -  Have long exposure to sunlight routinely or use tanning beds regularly

          -  Participate in regular vigorous exercise
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Invicro, Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 15, 2020</verification_date>
  <study_first_submitted>May 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

